Evidence map›Paper›PMID 34118395›Full record

ArticleNeuroImage2021

Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation.

Christopher G Schwarz, Terry M Therneau, Stephen D Weigand, Jeffrey L Gunter, Val J Lowe, Scott A Przybelski, Matthew L Senjem, Hugo Botha, Prashanthi Vemuri, Kejal Kantarci and 6 more

Open access · goldAbstract read
In one paragraph

Article in NeuroImage, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. EvaluatingJournal of neurology · 2025
    Article
  9. Integrating visual assessments and quantification methods for tau PET staging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning: Introducing THETA, a Novel Tau Summary Measure.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  11. Article
  12. Article
  13. Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Christopher G SchwarzDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA. Electronic address: schwarz.christopher@mayo.edu.
Terry M TherneauDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic and Foundation, Rochester, MN, USA.
Stephen D WeigandDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic and Foundation, Rochester, MN, USA.
Jeffrey L GunterDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA; Department of Information Technology, Mayo Clinic and Foundation, Rochester, MN, USA.
Val J LoweDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA.
Scott A PrzybelskiDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic and Foundation, Rochester, MN, USA.
Matthew L SenjemDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA; Department of Information Technology, Mayo Clinic and Foundation, Rochester, MN, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester 55905, MN, USA.
Mayo Clinic · US

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Longitudinal multi-modality imaging in progressive apraxia of speech (Diversity Supplement)R01DC012519 · NIDCD · MAYO CLINIC ROCHESTER · PI Jennifer Louise Whitwell · 2013 to 2026
$7.2M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG050603NIA NIH HHS R01 AG068206NIA NIH HHS R37 AG011378NIA NIH HHS R56 AG068206NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG045390NIDCD NIH HHS R01 DC012519NINDS NIH HHS R01 NS089757NINDS NIH HHS R01 NS097495NINDS NIH HHS R21 NS094684NINDS NIH HHS U01 NS100620NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

Since tau PET tracers were introduced, investigators have quantified them using a wide variety of automated methods. As longitudinal cohort studies acquire second and third time points of serial within-person tau PET data, determining the best pipeline to measure change has become crucial. We compared a total of 415 different quantification methods (each a combination of multiple options) according to their effects on a) differences in annual SUVR change between clinical groups, and b) longitudinal measurement repeatability as measured by the error term from a linear mixed-effects model. Our comparisons used MRI and Flortaucipir scans of 97 Mayo Clinic study participants who clinically either: a) were cognitively unimpaired, or b) had cognitive impairments that were consistent with Alzheimer's disease pathology. Tested methods included cross-sectional and longitudinal variants of two overarching pipelines (FreeSurfer 6.0, and an in-house pipeline based on SPM12), three choices of target region (entorhinal, inferior temporal, and a temporal lobe meta-ROI), five types of partial volume correction (PVC) (none, two-compartment, three-compartment, geometric transfer matrix (GTM), and a tau-specific GTM variant), seven choices of reference region (cerebellar crus, cerebellar gray matter, whole cerebellum, pons, supratentorial white matter, eroded supratentorial WM, and a composite of eroded supratentorial WM, pons, and whole cerebellum), two choices of region masking (GM or GM and WM), and two choices of statistic (voxel-wise mean vs. median). Our strongest findings were: 1) larger temporal-lobe target regions greatly outperformed entorhinal cortex (median sample size estimates based on a hypothetical clinical trial were 520-526 vs. 1740); 2) longitudinal processing pipelines outperformed cross-sectional pipelines (median sample size estimates were 483 vs. 572); and 3) reference regions including supratentorial WM outperformed traditional cerebellar and pontine options (median sample size estimates were 370 vs. 559). Altogether, our results favored longitudinally SUVR methods and a temporal-lobe meta-ROI that includes adjacent (juxtacortical) WM, a composite reference region (eroded supratentorial WM + pons + whole cerebellum), 2-class voxel-based PVC, and median statistics.

Indexed as

CarbolinesAgedAged, 80 and overBrainFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission Tomographytau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinestau ProteinsAV-1451Bias correctionChange over timeFlortaucipirGeometric transfer matrixGTMInhomogeneity correctionPartial volume correctionPrecisionPVCReference regionRegion spread functionRSFSUVRTau PET

Identifiers

PMID34118395
PMCPMC8407434
OpenAlexW3166058229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.